Results 11 to 20 of about 2,707 (157)
International Journal of Mycobacteriology, 2023 Background: Drug-resistant tuberculosis (DR-TB) is a public health concern that is difficult to treat, requiring long and complex treatment with highly effective drugs.
Oki Nugraha Putra +3 more
doaj +1 more source
EClinicalMedicine, 2020 Background: Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10–19 years) with injectable-free regimens containing these drugs in ...
Erika Mohr-Holland +9 more
doaj +1 more source
Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
Lung India, 2023 Tuberculosis is a leading cause of death in our country. Multidrug-resistant tuberculosis increases the morbidity and mortality due to severe manifestations and difficult and prolonged medications.
Vikas Marwah +3 more
doaj +1 more source
Extensive Lymphadenopathy in an HIV-Negative Patient With Multidrug-Resistant Tuberculosis. [PDF]
Respirol Case RepExtensive lymphadenopathy is uncommon in HIV‐negative patients with tuberculosis. This clinical image highlights the striking CT appearance of extensive extrapulmonary lymph node involvement in symptomatic multidrug‐resistant tuberculosis, even in the absence of HIV infection. ABSTRACT Tuberculous lymphadenitis is generally more severe in patients with
Araya T +5 more
europepmc +2 more sources
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
eLife, 2016 There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania ...
Stephen Patterson +8 more
doaj +1 more source
Туберкулез и болезни лёгких, 2021 The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.
A. E. Russkikh +4 more
doaj +1 more source
Туберкулез и болезни лёгких, 2023 The objective: to evaluate the toxicity of combinations of delamanid and drugs for treatment of drug resistant tuberculosis with different safety profiles in an experiment.Results.
G. N. Mozhokina +3 more
doaj +1 more source
Safety, Tolerability, and Pharmacokinetics of a Novel Nitroimidazooxazole Antitubercular Agent in Healthy Adults: A Phase I Trial. [PDF]
MedComm (2020)Mean blood drug concentration–time curves (linear and semi‐logarithmic) of JBD0131 in the (A) single‐dose group; (B) food‐affected group. ABSTRACT This study evaluated the safety, tolerability, and pharmacokinetics of JBD0131, a novel nitroimidazooxazole antitubercular agent, in healthy adults.
Miao J +9 more
europepmc +2 more sources
Emerging Infectious Diseases, 2023 New classes of antitubercular drugs, diarylquinolines and nitroimidazoles, have been associated with improved outcomes in the treatment of drug-resistant tuberculosis, but that success is threatened by emerging drug resistance.
James Millard +3 more
doaj +1 more source
The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors
Frontiers in Microbiology, 2021 Given the upsurge of drug-resistant tuberculosis worldwide, there is much focus on developing novel drug combinations allowing shorter treatment duration and a lower toxicity profile.
Kyle H. Rohde, Leonardo Sorci
doaj +1 more source